PEVIA Consortium Submits 1st Intermediate Report
Vevey 20 June, 2018 – On 19 June 2018, Ahmed Bouzidi gave a well-received presentation at the Interpat AGM in Munich, speaking on two topics that are currently a focus of EBE: 1) SME innovation and IP landscape, and 2) Impact of the SPC manufacturing waiver on EU innovative SMEs.
Ahmed Bouzidi pointed: « It’s essential for the entire pharmaceutical business to closely work with SMEs because they are more and more relying on them in order to secure their product pipeline ».
Ahmed Bouzidi added: « The SPC Manufacturing Waiver would create during a very limited period jobs in the generic field, but it will cause more direct and indirect job losses in innovative EU-based companies. It will also decrease R&D investments in the EU ».
INTERPAT is a non-profit association of research-based pharmaceutical companies which promotes effective intellectual property (IP) protection. Its representatives are the senior executives of its member companies who are responsible for IP and related IP matters. Visit www.interpat.org for more information.
Vaxeal Holding SA is headquartered in Vevey, Switzerland. The company, in partnership with leading international research institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families and initial programs have reached the pre-clinical stage in major disease segments. Visit www.vaxeal.net for more information.